Prospective interventional study shows restoration of vision in chronic central serous chorioretinopathy patients, implying potential effectiveness of anti-VEGF therapy.
The study evaluate the role of anti-vascular endothelial growth factors (Anti-Vegf) in the treatmentof chronic central serous chorioretinopathy (CSCR). It was a hospital base prospectiveinterventional non randomized study. Patients with history of chronic CSCR lasting for more than3 months were treated with intravitreal Bevacizumab 1.25mg or Ranibizumab 0.5mg aftermeasurement of best corrected visual acuity (BCVA), intraocular pressure (IOP), dilated fundusexamination and central macular thickness using OCT. Patient shows complete resolution ofsubretinal fluid and restoration of visual acuity to normal after 3months. In conclusion, intravitrealinjection of anti-vegf results in restoration of normal vision in patient with CSCR.
No takes yet. Share an insight, caveat, or question.
S.M et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: